Whiting USA Trust II EV/EBIT
Mi az Whiting USA Trust II EV/EBIT?
A EV/EBIT az Whiting USA Trust II - 0.32
Mi a EV/EBIT meghatározása?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT a Energy szektor a OTC-on cégekben a Whiting USA Trust II -hoz képest
Mit csinál Whiting USA Trust II?
Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions of the United States. Its oil and gas properties include interests in approximately 364.1 net producing oil and natural gas wells located in 42 predominately mature fields with established production profiles in 8 states. The company was founded in 2011 and is based in Houston, Texas. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation.
ev/ebit -hoz hasonló cégek Whiting USA Trust II
- Oncternal Therapeutics nak EV/EBIT 0.28 van
- Sulliden Mining Capital nak EV/EBIT 0.29 van
- J4 Ventures nak EV/EBIT 0.29 van
- Sulliden Mining Capital nak EV/EBIT 0.30 van
- Bio-Path Inc nak EV/EBIT 0.31 van
- Freeline Therapeutics plc nak EV/EBIT 0.31 van
- Whiting USA Trust II nak EV/EBIT 0.32 van
- Valencia Capital nak EV/EBIT 0.33 van
- BlueCity nak EV/EBIT 0.33 van
- Aclaris Therapeutics Inc nak EV/EBIT 0.35 van
- Zafgen nak EV/EBIT 0.35 van
- Xenetic Biosciences Inc nak EV/EBIT 0.35 van
- Ocwen nak EV/EBIT 0.35 van